Therapeutics: MicroRNA-150 (miR-150); FMS-like tyrosine kinase 3 (FLT3; CD135); FMS-like tyrosine kinase 3 ligand (FLT3LG)

Cancer

INDICATION: Acute myelogenous leukemia (AML); leukemia

Patient sample, cell culture and mouse studies suggest miR-150, a negative regulator of

Read the full 182 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE